Nearly 200 New Medicines in Development for Diabetes - - BioPharm International

ADVERTISEMENT

Nearly 200 New Medicines in Development for Diabetes



America’s biopharmaceutical research companies are currently developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide. These medicines in development, all either in clinical trials or under review by FDA, include 30 for type 1 diabetes, 100 for type 2, and 52 for diabetes-related conditions, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA).

According to the report, some of the initiatives being taken against diabetes include treatments that will improve glucose-dependent insulin secretion for type 2 diabetes, inhibit an enzyme linked to diabetic neuropathy, and stimulate and enhance the regeneration of insulin-producing cells for type 1 diabetes.

A new public-private partnership involving the National Institutes of Health, 10 biopharmaceutical companies, PhRMA, and several non-profit disease foundations aims to transform the current model for developing new diagnostics and treatments for certain diseases. The Accelerating Medicines Partnership will begin with three- to five-year pilot projects focused on three disease areas, including diabetes.

Source: Pharmaceutical Research and Manufacturers of America

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines

Click here